Main Title

1
Strategic Information To Support Procurement
Dr F. Renaud-Thery, B. Dongmo Nguimfack Aids
Medicines and Diagnostics Services, Health
Systems Strengthening HIV/AIDS Department, WHO
2
Why do countries need WHOs market intelligence?

• With a better knowledge of ARV market components,
  countries increase their performance in
  procurement practices which product to buy, from
  who and at what price
• Countries have had few sources of public
  information about HIV drug pricing and
  transactions
• Countries are struggling to cope with a massive
  increase in the value and volume of medicines
  needed for HIV/AIDS programmes
• Beneficiaries of ARV market intelligence state
  and non-state health sector procurement agents,
  ARV programme managers, and the patients

3
Prices vary within regions
300
271
Zimbabwe
Tanzania
Rwanda
238
234
South Africa
(Annual price in USD)
200
150
104
100
85
61
61
Nevirapine
AZT3TC
4
Prices vary within countries
600
Global Fund
536
IDA
500
Mission Pharma
Unicef
(Annual price in USD)
400
300
246
200
190
191
176
100
88
68
70
66
Lamivudine 300mg
D4T3TCNVP
Cambodia
5
What information is available and where?
Market Intelligence
Web-based tools

• Global Price Reporting Mechanisms
• 2. Regulatory database
• 3. API database
• 4. Patent database (in progress)

1. Transactions prices, volumes
and market shares 2. Registration
information 3. ARV active pharmaceutical
ingredients (API) 4. Patents
6
(No Transcript)
7
http//www.who.int/3by5/amds/price/hdd/
8
(No Transcript)
9
(No Transcript)
10
Regulatory status database http//www.who.int/hiv
/amds/patents_registration/drs/

• What
• Collect regulatory information and make it
  available in the public domain
• Contributors all RD and generic ARV producers

11
(No Transcript)
12
(No Transcript)
13
(No Transcript)
14
Patent database (in progress)

• WHAT
• Information on which medicines are patented,
  where, by how many patents, and for how long
• WHY
• When relevant patents expire
• When generic substitution and competition is
  possible

15

• www.who.int/hiv/amds